ERBB2 and breast cancer: Among the four primary molecular subtypes (luminal A, luminal B, HER2-positive, and triple negative), HER2-positive (HER2+) breast cancer is considered rather aggressive and accounts for 20–25 % of all breast cancer [2,3].